APA (7th ed.) Citation

Burmester, G. R., Coates, L. C., Cohen, S. B., Tanaka, Y., Vranic, I., Nagy, E., . . . Kinch, C. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Rheumatology & Therapy, 10(5), 1255. https://doi.org/10.1007/s40744-023-00576-8

Chicago Style (17th ed.) Citation

Burmester, Gerd R., et al. "Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis." Rheumatology & Therapy 10, no. 5 (2023): 1255. https://doi.org/10.1007/s40744-023-00576-8.

MLA (9th ed.) Citation

Burmester, Gerd R., et al. "Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis." Rheumatology & Therapy, vol. 10, no. 5, 2023, p. 1255, https://doi.org/10.1007/s40744-023-00576-8.